NCT01379430View on ClinicalTrials.gov

Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Malaria
Interventions
BIOLOGICAL

AdCh63 ME-TRAP followed by MVA ME-TRAP

AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly

BIOLOGICAL

AdCh63 ME-TRAP followed by MVA ME-TRAP

AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal

Trial Locations (1)

PO Box 43640, 00100

KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast, Kilifi

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER